ERBB2 and breast cancer: Specifically, tucatinib plus trastuzumab and capecitabine (TXC) and trastuzumab emtansine (TDM-1) are the two treatment options recommended as third-line therapies in HER2+ BC patients with two failed treatment lines [9].